Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mesoblast Ltd (MESO)
NASDAQ:MESO
MESO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.75 - $22.00
Previous CloseN/A
Volume155.35K
Average Volume (3M)662.23K
Market Cap
$2.30B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Feb 20, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding127,052,720
10 Day Avg. Volume437,239
30 Day Avg. Volume662,227
Standard Deviation0.36
R-Squared0.24
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)353.45
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$22.50Price Target Upside19.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Mesoblast News
PremiumCompany Announcements
Mesoblast Director Increases Share Holdings Significantly---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalRyoncil gains approval in the US for pediatric steroid refractory acute graft vs host disease, marking a significant milestone for Mesoblast and validating FDA's supportive stance on cell therapy.
Market OpportunityRyoncil is positioned for a market opportunity of approximately $500 million due to the high pricing range similar to CAR-T and gene therapy, driven by the high unmet need in pediatric SR-aGvHD.
Pipeline PotentialSignificant potential for Mesoblast in its late-stage pipeline, including heart failure (HF), with potentially two near-term filings, as well as the ongoing P3 in chronic lower back pain (CLBP).
Bears Say
CompetitionRyoncil's approval as the only drug for patients under 12 could provide a competitive advantage, especially in the 12-18 year-old segment where it overlaps with Jakafi.
Regulatory ChallengesThe committee voted 9-1 in favor of the data package supporting approval despite earlier negative briefing documents.
Regulatory RiskThe FDA's decision to allow filing based on existing data for remestemcel-L indicates a supportive trend for cell therapies, which could benefit Mesoblast's future prospects.
---
Ownership Overview
―
Insiders
0.01% Mutual Funds
0.48% Other Institutional Investors
98.97% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MESO FAQ
What was Mesoblast Ltd’s price range in the past 12 months?
Mesoblast Ltd lowest stock price was $1.75 and its highest was $22.00 in the past 12 months.
What is Mesoblast Ltd’s market cap?
Mesoblast Ltd’s market cap is $2.30B.
When is Mesoblast Ltd’s upcoming earnings report date?
Mesoblast Ltd’s upcoming earnings report date is Feb 20, 2025 which is in 14 days.
How were Mesoblast Ltd’s earnings last quarter?
Mesoblast Ltd released its earnings results on Nov 20, 2024. The company reported -$0.14 earnings per share for the quarter, the consensus estimate of -$0.14 by $0.
Is Mesoblast Ltd overvalued?
According to Wall Street analysts Mesoblast Ltd’s price is currently Undervalued.
Does Mesoblast Ltd pay dividends?
Mesoblast Ltd does not currently pay dividends.
What is Mesoblast Ltd’s EPS estimate?
Mesoblast Ltd’s EPS estimate is -0.28.
How many shares outstanding does Mesoblast Ltd have?
Mesoblast Ltd has 127,052,720 shares outstanding.
What happened to Mesoblast Ltd’s price movement after its last earnings report?
Mesoblast Ltd reported an EPS of -$0.14 in its last earnings report, expectations of -$0.14. Following the earnings report the stock price went down -4.529%.
Which hedge fund is a major shareholder of Mesoblast Ltd?
Currently, no hedge funds are holding shares in MESO
---
Mesoblast Stock Smart Score
Company Description
Mesoblast Ltd
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
---
MESO Stock 12 Month Forecast
Average Price Target
$22.50
▲(19.55% Upside)
Technical Analysis
Best Analysts Covering MESO
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+71.65%
reiterated a buy rating 2 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +71.65% per trade.
---